Additional clinical studies to investigate its mechanism of action include a double-blinded crossover trial in glucokinase–maturity-onset diabetes of the young (GCK-MODY) patients who suffered from a heterozygous GK gene inactive mutation and defect in second phase insulin secretion in response to a glucose challenge. The gene discussed is GCK; the disease is type 2 diabetes mellitus.